Genetic polymorphism of S mephenytoin hydroxylation.
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
Hydroxylation polymorphism of debrisoquine and mephenytoin
in European populations.
Because fosphenytoin is water soluble and has a more neutral pH compared to phenytoin, it is more rapidly and less painfully absorbed when given via the IV or IM route.[5,9] Ethotoin and mephenytoin
, second line AEDs in this class, are rapidly absorbed through the gastrointestinal (GI) system.
Family study of a genetically determined deficiency of mephenytoin hydroxylation in man.
Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
For instance, CYP2A6 is responsible for the main metabolism of nicotine, and CYP2C19 is responsible for mephenytoin
metabolism. The cytochrome CYP2D6 deserves some special considerations.
Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin
. Int Clin Psychopharmacol 1986;1:102-12.
Other drugs assayed at therapeutic concentrations that had no interference included carbamazepine and its epoxide and hydroxy metabolites, oxcarbazepine and it monohydroxylated metabolite, zonisamide, levetiracetam, phenytoin and its metabolites, felbamate, lamotrigine, clonazepam, phenobarbital, primidone, acetaminophen, salicylate, ibuprofen, amitriptyline, nortriptyline, desipramine, doxepin and nordoxepin, imipramine, valproic acid, topiramate, mephenytoin
and Nirvanol, amiodarone and desethylamiodarone, methsuximide and normethsuximide, ethotoin, clozapine, and sertraline.
The major genetic defect responsible for the polymorphism of S mephenytoin metabolism in humans.
Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
A genetic polymorphism in the metabolism of the anticonvulsant drug mephenytoin in humans is a prime example of interracial and individual variability in drug metabolism.
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*28) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998;286:1490-5.
Cytochrome P450 Gene family isoenzymes Representative substrates CYP1 P450IA2 Caffeine, theophylline CYP2 P450IIC19 Mephenytoin
, phenylbutazone P450IID6 Debrisoquin, metoprolol P450IIE1 Ethanol, acetaminophen CYP3 P450IIIA4 Erythromycin, cyclosporine Table 3.
A second well-characterized CYP-related drug metabolism polymorphism in humans is associated with the 4'-hydroxylation of the S-enantiomer of the anticonvulsant mephenytoin